Amit Bleiweiss

Amit Bleiweiss is a senior data scientist at NVIDIA, where he focuses on large language models and generative AI. He has 25 years of experience in applied machine learning and deep learning, with over 50 patents and publications in the domain. Amit received his MSc from Hebrew University of Jerusalem, where he specialized in machine learning.
Amit Bleiweiss

Posts by Amit Bleiweiss

Agentic AI / Generative AI

Using NVFP4 Low-Precision Model Training for Higher Throughput Without Losing Accuracy

As the sizes of AI models and datasets continue to increase, relying only on higher-precision BF16 training is no longer sufficient. Key challenges such as... 8 MIN READ
Decorative image.
Agentic AI / Generative AI

How to Enhance RAG Pipelines with Reasoning Using NVIDIA Llama Nemotron Models

A key challenge for retrieval-augmented generation (RAG) systems is handling user queries that lack explicit clarity or carry implicit intent. Users often... 13 MIN READ
Agentic AI / Generative AI

Scaling to Millions of Tokens with Efficient Long-Context LLM Training

The evolution of large language models (LLMs) has been marked by significant advancements in their ability to process and generate text. Among these... 7 MIN READ
Decorative AI image.
MLOps

Spotlight: Build Scalable and Observable AI Ready for Production with Iguazio's MLRun and NVIDIA NIM

The collaboration between Iguazio (acquired by McKinsey) and NVIDIA empowers organizations to build production-grade AI solutions that are not only... 7 MIN READ
Decorative image.
Agentic AI / Generative AI

Spotlight: Qodo Innovates Efficient Code Search with NVIDIA DGX

Large language models (LLMs) have enabled AI tools that help you write more code faster, but as we ask these tools to take on more and more complex tasks, there... 8 MIN READ
Agentic AI / Generative AI

Spotlight: Drug Discovery Startup Protai Advances Complex Structure Prediction with AlphaFold, Proteomics, and NVIDIA NIM

Generative AI, especially with breakthroughs like AlphaFold and RosettaFold, is transforming drug discovery and how biotech companies and research laboratories... 10 MIN READ